Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 n Patients With Unresectable Pancreatic Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Anchiano Therapeutics
- 03 Nov 2010 Results reported in a Tikcro (shareholders in BioCancell Therapeutics) media release.
- 02 Nov 2010 Results reported in a BioCancell media release.
- 07 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.